Protective antigen as a correlative marker for anthrax in animal models

Infection and Immunity

Volumn 74, Issue 10, 2006, Pages 5871-5876

  Kobiler, David ^a   Weiss, Shay ^a   Levy, Haim ^a   Fisher, Morly ^a   Mechaly, Adva ^a   Pass, Avi ^a   Altboum, Zeev ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; BACTERIAL ANTIGEN; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

AIRBORNE INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIGEN DETECTION; ARTICLE; BACILLUS ANTHRACIS; BACTEREMIA; BACTERIAL SPORE; BLOOD LEVEL; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; FATALITY; GUINEA PIG; IMMUNODETECTION; INHALATION; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RABBIT; RELIABILITY; TREATMENT OUTCOME;

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACTEREMIA; BACTERIAL TOXINS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; GUINEA PIGS; PNEUMONIA, BACTERIAL; RABBITS;

EID: 33749265873     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00792-06     Document Type: Article

References (31)

1. Albrink, W. S., and R. J. Goodlow. 1959. Experimental inhalation anthrax in the chimpanzee. Am. J. Pathol. 35:1055-1065.
2. Altboum, Z., Y. Gozes, A. Barnea, A. Pass, M. White, and D. Kobiler. 2002. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect. Immun. 70:6231-6241.
3. Bartlett, J. G., T. V. Inglesby, Jr., and L. Borio. 2002. Management of anthrax. Clin. Infect. Dis. 35:851-858.
4. Begier, E. M. 2005. Gram-positive rod surveillance for early anthrax detection. Emerg. Infect. Dis. 11:1483-1486.
5. Berdjis, C. C., C. A. Gleiser, H. A. Hartman, R. W. Kuehne, and W. S. Gochenour. 1962. Pathogenesis of respiratory anthrax in Macaca mulatta. Br. J. Exp. Pathol. 43:515-524.
6. Brachman, P. S. 1980. Inhalation anthrax. Ann. N. Y. Acad. Sci. 353:83-93.
7. Brachman, P. S., A. F. Kaufmann, and F. G. Dalldorf. 1966. Industrial inhalation anthrax. Bacteriol. Rev. 30:646-659.
8. Brook, I. 2002. The prophylaxis and treatment of anthrax. Int. J. Antimicrob. Agents 20:320-325.
9. Centers for Disease Control and Prevention. 2001. Update: investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. Morb. Mortal. Wkly. Rep. 50:973-976.
10. Collier, R., and J. Young. 2003. Anthrax toxins. Annu. Rev. Cell Dev. Biol. 19:45-70.
11. Dixon, T. C., M. Meseslson, J. Guilemin, and P. Hanna. 1999. Anthrax. N. Engl. J. Med. 341:815-826.
12. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
13. Fish, D. C., and R. E. Lincoln. 1968. In vivo-produced anthrax toxin. J. Bacteriol. 95:919-924.
14. Guidi-Rontani, C., and M. Mock. 2002. Macrophage interactions. Curr. Top. Microbiol. Immunol. 271:115-141.
15. Hanna, P. 1998. Anthrax pathogenesis and host response. Curr. Top. Microbiol. Immunol. 225:13-35.
16. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
17. Jernigan, D. B., P. L. Raghunathan, B. P. Bell, R. Brechner, E. A. Bresnitz, J. C. Butler, M. Cetron, M. Cohen, T. Doyle, M. Fischer, C. Greene, K. S. Griffith, J. Guarner, J. L. Hadler, J. A. Hayslett, R. Meyer, L. R. Petersen, M. Phillips, R. Pinner, T. Popovic, C. P. Quinn, J. Reefhuis, D. Reissman, N. Rosenstein, A. Schuchat, W. J. Shieh, L. Siegal, D. L. Swerdlow, F. C. Tenover, M. Traeger, J. W. Ward, I. Weisfuse, S. Wiersma, K. Yeskey, S. Zaki, D. A. Ashford, B. A. Perkins, S. Ostroff, J. Hughes, D. Fleming, J. P. Koplan, and J. L. Gerberding. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 8:1019-1028.
18. Jernigan, J. A., D. S. Stephens, D. A. Ashford, C. Omenaca, M. S. Topiel, M. Galbraith, M. Tapper, T. L. Fisk, S. Zaki, T. Popovic, R. F. Meyer, C. P. Quinn, S. A. Harper, S. K. Fridkin, J. J. Sejvar, C. W. Shepard, M. McConnell, J. Guarner, W. J. Shieh, J. M. Malecki, J. L. Gerberding, J. M. Hughes, and B. A. Perkins. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944.
19. Jernigan, J. A., D. S. Stephens, D. A. Ashford, and B. A. Perkins. 2003. Industry-related outbreak of human anthrax. Emerg. Infect. Dis. 9:1657-1659.
20. Klein, F., J. S. Walker, D. F. Fitzpatrick, R. E. Lincoln, B. G. Mahlandt, W. I. Jones, Jr., J. P. Dobbs, and K. J. Hendrix. 1966. Pathophysiology of anthrax. J. Infect. Dis. 116:123-138.
21. Klimpel, K. R., N. Arora, and S. H. Leppla. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093-1100.
22. Levy, H., M. Fisher, N. Ariel, Z. Altboum, and D. Kobiler. 2005. Identification of strain specific markers in Bacillus anthracis by random amplification of polymorphic DNA. FEMS Microbiol. Lett. 244:199-205.
23. Meselson, M., J. Guillemin, M. Hugh-Jones, A. Langmuir, I. Popova, A. Shelokov, and O. Yampolskaya. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266:1202-1208.
24. Moayeri, M., and S. H. Leppla. 2004. Anthrax toxins in pathogenesis. Curr. Opin. Microbiol. 7:19-24.
25. Mourez, M. 2004. Anthrax toxins. Rev. Physiol. Biochem. Pharmacol. 152:135-164.
26. Reuveny, S., M. White, Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893.
27. Ross, J. M. 1957. The pathogenesis of anthrax following the administration of spores by respiratory route. J. Pathol. Bacteriol. 73:485-494.
28. Turnbull, P. C. B. 1998. Guidelines for the surveillance and control of anthrax in humans and animals (publication no. WHO/EMC/ZDI./98.6). Department of Communicable Diseases Surveillance and Response, World Health Organization, Geneva, Switzerland.
29. Vitale, G., R. Pellizzari, C. Recchi, G. Napolitani, M. Mock, and C. Montecucco. 1998. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248:706-711.
30. Walker, J. S., F. Klein, R. E. Lincoln, and A. L. Fernelius. 1967. Temperature response in animals infected with Bacillus anthracis. J. Bacteriol. 94:552-556.
31. Weiss, S., D. Kobiler, H. Levy, H. Marcus, A. Pass, N. Rothschild, and Z. Altboum. 2006. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 74:394-398.